Teng Fei

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

Nature communications

Life science alliance

Nature biomedical engineering

Advanced biosystems

Northeastern University

Tsinghua University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Northeastern University Sep 01 2016

China

Professor

Harvard Medical School/Dana-Farber Cancer Insititute May 02 2011 - Sep 01 2016

United States

Postdoctoral Research Fellow

Education History

Tsinghua University Sep 01 2005 - Jul 01 2010

China

PHD

Northeastern University Sep 01 2001 - Jul 01 2005

China

BSC

Publications

Chunge Zhong, Wen-Jie Jiang, Yingjia Yao, Zexu Li, You Li, Shengnan Wang, Xiaofeng Wang, Wenjuan Zhu, Siqi Wu, Jing Wang, Shuangshuang Fan, Shixin Ma, Yeshu Liu, Han Zhang, Wenchang Zhao, Lu Zhao, Yi Feng, Zihan Li, Ruifang Guo, Li Yu, Fengyun Pei, Jun Hu, Xingzhi Feng, Zi-Huan Yang, Zhengjia Yang, Xueying Yang, Yue Hou, Danni Zhang, Dake Xu, Ren Sheng, Yihao Li, Lijun Liu, Hua-Jun Wu, Jun Huang, Teng Fei
CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer. Nature communications 15 (1) (2024)
Chunge Zhong, Wen-Jie Jiang, Yingjia Yao, Zexu Li, You Li, Shengnan Wang, Xiaofeng Wang, Wenjuan Zhu, Siqi Wu, Jing Wang, Shuangshuang Fan, Shixin Ma, Yeshu Liu, Han Zhang, Wenchang Zhao, Lu Zhao, Yi Feng, Zihan Li, Ruifang Guo, Li Yu, Fengyun Pei, Jun Hu, Xingzhi Feng, Zi-Huan Yang, Zhengjia Yang, Xueying Yang, Yue Hou, Danni Zhang, Dake Xu, Ren Sheng, Yihao Li, Lijun Liu, Hua-Jun Wu, Jun Huang, Teng Fei
CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer. Nature communications 15 (1) (2024)
Chunge Zhong, Wen-Jie Jiang, Yingjia Yao, Zexu Li, You Li, Shengnan Wang, Xiaofeng Wang, Wenjuan Zhu, Siqi Wu, Jing Wang, Shuangshuang Fan, Shixin Ma, Yeshu Liu, Han Zhang, Wenchang Zhao, Lu Zhao, Yi Feng, Zihan Li, Ruifang Guo, Li Yu, Fengyun Pei, Jun Hu, Xingzhi Feng, Zi-Huan Yang, Zhengjia Yang, Xueying Yang, Yue Hou, Danni Zhang, Dake Xu, Ren Sheng, Yihao Li, Lijun Liu, Hua-Jun Wu, Jun Huang, Teng Fei
CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer. Nature communications 15 (1) (2024)
Zexu Li, Zihan Li, Xiaolong Cheng, Shengnan Wang, Xiaofeng Wang, Shixin Ma, Zhiyan Lu, Han Zhang, Wenchang Zhao, Zhisong Chen, Yingjia Yao, Cheng Zhang, Lumen Chao, Wei Li, Teng Fei
Intrinsic targeting of host RNA by Cas13 constrains its utility. Nature biomedical engineering (2023)
Xiaolong Cheng, Zexu Li, Ruocheng Shan, Zihan Li, Shengnan Wang, Wenchang Zhao, Han Zhang, Lumen Chao, Jian Peng, Teng Fei, Wei Li
Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nature communications 14 (1) (2023)
Xiaolong Cheng, Zexu Li, Ruocheng Shan, Zihan Li, Shengnan Wang, Wenchang Zhao, Han Zhang, Lumen Chao, Jian Peng, Teng Fei, Wei Li
Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nature communications 14 (1) (2023)
Xiaolong Cheng, Zexu Li, Ruocheng Shan, Zihan Li, Shengnan Wang, Wenchang Zhao, Han Zhang, Lumen Chao, Jian Peng, Teng Fei, Wei Li
Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nature communications 14 (1) (2023)
Xiaolong Cheng, Zexu Li, Ruocheng Shan, Zihan Li, Shengnan Wang, Wenchang Zhao, Han Zhang, Lumen Chao, Jian Peng, Teng Fei, Wei Li
Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nature communications 14 (1) (2023)
Xiaolong Cheng, Zexu Li, Ruocheng Shan, Zihan Li, Shengnan Wang, Wenchang Zhao, Han Zhang, Lumen Chao, Jian Peng, Teng Fei, Wei Li
Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nature communications 14 (1) (2023)
Aina He, Lanjing Ma, Yujing Huang, Haijiao Zhang, Wei Duan, Zexu Li, Teng Fei, Junqing Yuan, Hao Wu, Liguo Liu, Yueqing Bai, Wentao Dai, Yonggang Wang, Hongtao Li, Yong Sun, Yaling Wang, Chunyan Wang, Ting Yuan, Qingcheng Yang, Songhai Tian, Min Dong, Ren Sheng, Dongxi Xiang
Correction: CDKL3 promotes osteosarcoma progression by activating Akt/PKB. Life science alliance 5 (11) (2022)
Zexu Li, Teng Fei
Improving Cancer Immunotherapy with CRISPR-Based Technology. Advanced biosystems 4 (11) (2020)
Aina He, Lanjing Ma, Yujing Huang, Haijiao Zhang, Wei Duan, Zexu Li, Teng Fei, Junqing Yuan, Hao Wu, Liguo Liu, Yueqing Bai, Wentao Dai, Yonggang Wang, Hongtao Li, Yong Sun, Yaling Wang, Chunyan Wang, Ting Yuan, Qingcheng Yang, Songhai Tian, Min Dong, Ren Sheng, Dongxi Xiang
CDKL3 promotes osteosarcoma progression by activating Akt/PKB. Life science alliance 3 (5) (2020)

Teng Fei.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Teng Fei